Barclays Analyst Predicts Biotech M&A Market Reopening After Prolonged Downturn
Barclays’ Emily Field, Head of U.S. Biopharma Equity Research, has stated that the biotechnology merger and acquisition (M&A) market is reopening after a prolonged freeze driven by uncertainty around drug pricing policies during the Trump administration and capital constraints. She highlighted recent oncology breakthroughs from companies like Moderna and Merck in cancer vaccines as catalysts for renewed M&A activity. Field pointed to positive developments such as AbbVie’s $10.9 billion Apogee acquisition, despite a 36% drop in Humira sales, indicating that large pharma firms remain committed to deal-making. Moderna and Merck's melanoma vaccine reduced recurrence risk by 49%, leading to significant stock gains for both companies. Revolution Medicines also saw strong results from its pancreatic cancer drug daraxonrasib. The analyst emphasized the importance of patent expirations as a driver for future M&A, noting that large pharma firms are actively seeking new assets to replace aging products.
Tickers: $ABBV $BARC $MRK $MRNA $RVMD
Topics: Biotech M&A Capital markets Pharmaceutical innovation